Discordance in the diagnostic assessment of vulnerable plaques between radiofrequency intravascular ultrasound versus optical coherence tomography among patients with acute myocardial infarction: insights from the IBIS-4 study.
Fibroatheroma
Intravascular ultrasound
Optical coherence tomography
Radiofrequency
Journal
The international journal of cardiovascular imaging
ISSN: 1875-8312
Titre abrégé: Int J Cardiovasc Imaging
Pays: United States
ID NLM: 100969716
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
26
01
2021
accepted:
02
05
2021
pubmed:
9
7
2021
medline:
16
10
2021
entrez:
8
7
2021
Statut:
ppublish
Résumé
We aimed to evaluate the diagnostic agreement between radiofrequency (RF) intravascular ultrasound (IVUS) and optical coherence tomography (OCT) for thin-cap fibroatheroma (TCFA) in non-infarct-related coronary arteries (non-IRA) in patients with ST-segment elevation myocardial infarction (STEMI). In the Integrated Biomarker Imaging Study (IBIS-4), 103 STEMI patients underwent OCT and RF-IVUS imaging of non-IRA after successful primary percutaneous coronary intervention and at 13-month follow-up. A coronary lesion was defined as a segment with ≥ 3 consecutive frames (≈1.2 mm) with plaque burden ≥ 40% as assessed by grayscale IVUS. RF-IVUS-derived TCFA was defined as a lesion with > 10% confluent necrotic core abutting to the lumen in > 10% of the circumference. OCT-TCFA was defined by a minimum cap thickness < 65 μm. The two modalities were matched based on anatomical landmarks using a dedicated matching software. Using grayscale IVUS, we identified 276 lesions at baseline (N = 146) and follow-up (N = 130). Using RF-IVUS, 208 lesions (75.4%) were classified as TCFA. Among them, OCT identified 14 (6.7%) TCFA, 60 (28.8%) thick-cap fibroatheroma (ThCFA), and 134 (64.4%) non-fibroatheroma. All OCT-TCFA (n = 14) were confirmed as RF-TCFA. The concordance rate between RF-IVUS and OCT for TCFA diagnosis was 29.7%. The reasons for discordance were: OCT-ThCFA (25.8%); OCT-fibrous plaque (34.0%); attenuation due to calcium (23.2%); attenuation due to macrophage (10.3%); no significant attenuation (6.7%). There was a notable discordance in the diagnostic assessment of TCFA between RF-IVUS and OCT. The majority of RF-derived TCFA were not categorized as fibroatheroma using OCT, while all OCT-TCFA were classified as TCFA by RF-IVUS.ClinicalTrials.gov Identifier NCT00962416.
Identifiants
pubmed: 34236570
doi: 10.1007/s10554-021-02272-6
pii: 10.1007/s10554-021-02272-6
pmc: PMC8494667
doi:
Banques de données
ClinicalTrials.gov
['NCT00962416']
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2839-2847Subventions
Organisme : Swiss National Science Foundation
ID : 33CM30-124112 and 310030-118353
Pays : Switzerland
Informations de copyright
© 2021. The Author(s).
Références
JACC Cardiovasc Imaging. 2012 Mar;5(3 Suppl):S1-9
pubmed: 22421222
Cardiovasc Diabetol. 2016 Oct 10;15(1):144
pubmed: 27724869
JACC Cardiovasc Imaging. 2013 Jan;6(1):86-95
pubmed: 23328566
Int Heart J. 2011;52(3):175-9
pubmed: 21646741
J Am Coll Cardiol. 2012 Mar 20;59(12):1058-72
pubmed: 22421299
Am J Cardiol. 2008 Oct 15;102(8):975-9
pubmed: 18929696
Lancet. 2019 Nov 2;394(10209):1629-1637
pubmed: 31570255
Circ J. 2009 Jun;73(6):1086-91
pubmed: 19359816
J Am Coll Cardiol. 2007 Sep 4;50(10):940-9
pubmed: 17765120
J Am Coll Cardiol. 2014 Aug 19;64(7):672-80
pubmed: 25125298
Eur Heart J. 2020 Jan 14;41(3):383-391
pubmed: 31504405
Am J Cardiol. 2006 Jul 15;98(2):156-9
pubmed: 16828584
Ultrasound Med Biol. 2001 Oct;27(10):1319-31
pubmed: 11731045
Circ Cardiovasc Imaging. 2013 Sep;6(5):655-64
pubmed: 23960215
Eur Heart J. 2018 Sep 14;39(35):3281-3300
pubmed: 29790954
EuroIntervention. 2009 Jun;5(2):177-89
pubmed: 20449928
JACC Cardiovasc Imaging. 2019 Aug;12(8 Pt 1):1518-1528
pubmed: 30553686
Eur Heart J. 2008 May;29(9):1136-46
pubmed: 18397871
Circ Cardiovasc Imaging. 2015 Oct;8(10):e003487
pubmed: 26429760
Am Heart J. 2006 Oct;152(4):755.e1-4
pubmed: 16996853
J Am Coll Cardiol. 2018 Oct 23;72(17):2012-2021
pubmed: 30336824
J Am Coll Cardiol. 2018 Oct 23;72(17):2003-2011
pubmed: 30336823
Eur Heart J. 2014 Mar;35(10):639-47
pubmed: 24255128
Eur Heart J. 2015 Feb 21;36(8):490-500
pubmed: 25182248
JACC Cardiovasc Imaging. 2011 Jul;4(7):810-3
pubmed: 21757174
EuroIntervention. 2012 Apr;7(12):1435-43
pubmed: 22301368
N Engl J Med. 2011 Jan 20;364(3):226-35
pubmed: 21247313
Circ Cardiovasc Imaging. 2010 Jul;3(4):384-91
pubmed: 20460496
EuroIntervention. 2017 Jun 20;13(3):303-311
pubmed: 27973332
EuroIntervention. 2007 May;3(1):113-20
pubmed: 19737694
J Am Coll Cardiol. 2017 May 23;69(20):2502-2513
pubmed: 28521888
Circulation. 2002 Sep 24;106(13):1640-5
pubmed: 12270856
J Am Coll Cardiol. 2006 Apr 18;47(8 Suppl):C13-8
pubmed: 16631505
JACC Cardiovasc Imaging. 2011 Aug;4(8):894-901
pubmed: 21835382
JAMA. 2012 Aug 22;308(8):777-87
pubmed: 22910755
EuroIntervention. 2011 Apr;6(9):1123-30, 9
pubmed: 21518687
J Am Coll Cardiol. 2017 Feb 14;69(6):644-657
pubmed: 27989887